Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100554 | 0.80 | KMT2A (0.56) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4100184 | 0.79 | KMT2A (0.46) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4100515 | 0.76 | ANO1 (0.35) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4105837 | 0.75 | CNR2 (0.44) | KMT2AALDH1A1MEN1CYP1A2ANO1 | |
| SCHEMBL4101837 | 0.74 | ALDH1A1 (0.40) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4101325 | 0.74 | ALDH1A1 (0.33) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4114296 | 0.73 | KMT2A (0.40) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4101815 | 0.73 | MEN1 (0.58) | KMT2AALDH1A1MEN1GAAL3MBTL1 | |
| SCHEMBL4269317 | 0.72 | NPC1 (0.49) | KMT2AALDH1A1MEN1CYP1A2RAB9A | |
| SCHEMBL4107622 | 0.71 | ALDH1A1 (0.41) | KMT2AALDH1A1MEN1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | claimed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | CHRNA7, CHRNA1, CHRNA5 | KMT2A 1400/4885ALDH1A1 505/4885MEN1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.